Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis

Company Overview

Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.

The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases. The most advanced oncology program, VB10.16, is a therapeutic vaccine targeting HPV16-associated lesions and cancers, currently evaluated in multiple clinical trials. In parallel, a personalized neoantigen vaccine program, VB10.NEO, is being developed to address patient-specific tumor antigens. On the infectious disease front, Nykode is exploring prophylactic vaccine candidates designed to combat pathogens with high unmet medical need, leveraging insights from its immunomodulation platform.

Founded by immunology experts Dr. Inger Sandlie and Professor Bjarne Bogen, the company originally operated under the name Vaccibody ASA until a rebranding to Nykode Therapeutics in 2021. Since its inception, Nykode has established research collaborations and clinical trial sites across Europe and North America, reflecting its commitment to global patient impact. The company is led by a management team with extensive experience in vaccine development and biopharmaceutical commercialization, including CEO Gunn Hedlund, who has steered the organization through multiple clinical milestones and strategic partnerships.

Key Stats

• Today's Range: $0.20 to $0.20
• 50-Day Range: $0.17 to $0.21
• 52-Week Range: $0.17 to $0.39
• Volume: N/A
• Average Volume: 3,692 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VACBF Stock Analysis - Frequently Asked Questions

How have VACBF shares performed this year?

Nykode Therapeutics AS's stock was trading at $0.2408 at the start of the year. Since then, VACBF shares have decreased by 16.9% and is now trading at $0.20.

How do I buy shares of Nykode Therapeutics AS?

Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VACBF
• CIK: N/A
• Web: nykode.com
• Phone: 47-22-95-81-93
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A